IndustryCompany release

Ironwood raises 2026 guidance as LINZESS sales growth lifts third-quarter revenue to $133M

🇺🇸 Ironwood Pharmaceuticals Inc (IRWD) · Thu 05 Nov 2026

The US drugmaker now expects LINZESS net sales of $1.20-$1.25bn, while its confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome continues.

Ironwood Pharmaceuticals reported third-quarter 2026 results on 5 November and raised its full-year financial guidance, citing growth for its irritable bowel syndrome and constipation medicine LINZESS (linaclotide).

The company now expects LINZESS net sales in the US of $1.20-$1.25 billion for 2026. It also guides to total revenue of $485-$510 million for the year.

Third-quarter revenue came in at $133.0 million, and the company reported GAAP net income of $59.8 million for the period.

On the pipeline, Ironwood said the confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure is ongoing. All planned international clinical trial applications have been submitted and are either under review or already approved, according to the company.

What it means for your team

  • Regulatory teams tracking apraglutide should note that all planned international clinical trial applications are filed and under review or approved, so STARS-2 site activation depends on those outcomes.
  • Market-access teams can read the raised LINZESS guidance as a sign of continued US commercial momentum for linaclotide.
  • The source summary gives no details on STARS-2 timelines, enrolment or readout dates, so none should be assumed.

Company's press release (SEC filing): Ironwood Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Ironwood Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →